A Study of TAK-755 in Adults With Acute Ischemic Stroke (NCT07392450)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke
🩺 Plain-English Summary (8th-Grade Level)
Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible. The main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking. The participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Neurology — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (60 Sites)
Showing the first 25 of 60 sites.
- HonorHealth Neurology — Scottsdale, Arizona
- University of Arizona — Tucson, Arizona
- University of California San Francisco — San Francisco, California
- Massachusetts General Hospital — Boston, Massachusetts
- University at Buffalo — Buffalo, New York
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- HCA Houston Healthcare - North Cypress — Cypress, Texas
- Neurology Consultants of Dallas, PA — Dallas, Texas
- Ziekenhuis Oost-Limburg — Genk, Limburg
- Universitair Ziekenhuis Gent (Belgium,Ghent) — Ghent, Oost-Vlaanderen
- AZ Groeninge — Kortrijk, WVL
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman — Liège,
- Groupe sante CHC - Clinique du MontLegia — Liège,
- Porto Alegre Clinical Hospital (HCPA) — Porto Alegre, Rio Grande do Sul
- Hospital Moinhos de Vento — Porto Alegre, Rio Grande do Sul
- Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu — Botucatu, São Paulo
- Universidade Estadual de Campinas (UNICAMP) — Campinas, São Paulo
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirao Preto - Universidade de Sao Paulo — Ribeirão Preto, São Paulo
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto — São José do Rio Preto, São Paulo
- Hospital Sao Paulo / Escola Paulista de Medicina da Universidade Federal de Sao Paulo (EPM/UNIFESP) — São Paulo, São Paulo
- Beijing Tiantan Hospital, Capital Medical University — Beijing, Beijing Municipality
- Nanshi Hospital of Nanyang — Nanyang, Henan
- The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu
- Qilu Hospital of Shandong University — Jinan, Shandong
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Ischemic Stroke
- EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial) — Little Rock, Arkansas
- PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke — Edmonton, Alberta
- An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke — Buffalo, New York
- Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose — Houston, Texas
- Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke — Richmond, British Columbia
- Quelling of Excitotoxicity in Acute Stroke With Ketamine — Wynnewood, Pennsylvania
Explore by condition: All Acute Ischemic Stroke clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.